Thus, we predict that treatment with TGF-β antagonists will have significantly greater anti-metastatic impact when applied in the context of a syngeneic host, in which they will act by a cooperative mechanism that involves several different cellular compartments, including the CD8+ T cells, NK cells, the microvasculature, osteoclasts and the tumor cells themselves [54]. Here, CD8A is linked to neoplasm.